Cancer clinical trials in the region Pays de la Loire
436 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Sarcoma and GIST
#NCT07218926
#2025-522229-37-00
Required histologic types
GIST
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
KIT
PDGFRA
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
GlaxoSmithKline
Phase 3
Lung cancer
#NCT07185997
#2025-522151-26-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
Bispecific T-cell engager antibodies
7 recruiting sites
ArriVent BioPharma, Inc
Phase 3
Endometrial cancer
#NCT07044336
#2024-518777-34-00
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
15 recruiting sites
AstraZeneca
Phase 3
Lymphoma
CLL & Richter's syndrome
#NCT05254743
#2023-507699-38-00
Required histologic types
B cell lymphoma
CLL (Chronic Lymphocytic Leukemia)
Required histologic sub types
Lymphocytic lymphoma
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min
50-60 ml/min
30-50 ml/min
Required genetic anomalies
Other mutation
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
10 recruiting sites
Loxo Oncology
Phase 3
Kidney cancer
#NCT07227402
#2024-517136-21-00
Required histologic types
Clear cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Immunotherapy
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
11 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Endometrial cancer
#NCT07166094
Required histologic sub types
Endometrioid adenocarcinoma
Serous adenocarcinoma
Clear cell carcinoma
Dedifferentiated and undifferentiated endometrial ...
Other
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
13 recruiting sites
Genmab
Phase 3
Multiple myeloma
#NCT06615479
#2024-515279-37-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
Monoclonal antibodies
Proteasome inhibitor
Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
Multiple myeloma
#NCT06918002
#2024-516418-39-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
62 recruiting sites
Intergroupe Francophone du Myélome
Phase 3
Multiple myeloma
#NCT06152575
#2023-507871-23-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
Monoclonal antibodies
Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
13 recruiting sites
Pfizer
Phase 3
Multiple myeloma
#NCT05243797
#2023-510384-36-00
Required histologic types
Symptomatic multiple myeloma
Required number of previous lines of therapy
None
Required previous treatments
Monoclonal antibodies
Autologous stem cell transplant
Proteasome inhibitor
Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
Car-T
9 recruiting sites
European Myeloma Network B.V.